The evaluation of the effectiveness, safety and tolerability of treatment, using a specialized prostate-specific membrane antigen (PSMA) labeled with Lutetium177, in patients with recurrent and/or metastatic adenoid cystic carcinoma originating from the salivary glands - an open, non-commercial clinical trial
This research is a medical study looking into a new treatment for a specific and rare type of cancer called adenoid cystic carcinoma. This cancer typically begins in the salivary glands. The treatment being studied is called Pluvicto, which uses a special substance designed to target the cancer cells. Investigators want to understand if this treatment is safe for patients and how well it works. They are particularly interested in patients whose cancer has reappeared or spread to other parts of the body. This study is an important step in finding better ways to help those living with this condition. It's an open, non-commercial trial, meaning it's not funded by a drug company, and the results will be openly shared.
At a glance
What is this study about?
This clinical trial is exploring a new way to treat a specific and uncommon type of cancer known as adenoid cystic carcinoma. This kind of cancer usually starts in the glands that produce saliva, located in your mouth and throat. Doctors are testing a new medicine called Pluvicto. This medicine is special because it uses a technique that targets cancer cells more precisely.
The main goal of this study is to find out how safe the Pluvicto treatment is and what side effects patients might experience. They will also be looking to see how well it works in shrinking the cancer or stopping it from growing. This is especially important for patients whose cancer has returned after previous treatments or has spread to other parts of their body.
By taking part, you could help doctors learn more about this promising new treatment. The information gathered from this study could lead to better treatment options for people with adenoid cystic carcinoma in the future. It's an important step in advancing our understanding and care for this condition.
Key takeaways
- This study is for a rare salivary gland cancer called adenoid cystic carcinoma.
- It's testing a new medicine called Pluvicto which targets cancer cells.
- The main goals are to check the treatment's safety and how well it works.
- It's for patients whose cancer has returned or spread.
- Participants will be closely monitored for at least two years after treatment.
- You can withdraw from the study at any time.
Who may be eligible?
To be considered for this study, you would need to be 18 years old or older. The study is open to both men and women.
Beyond these basic requirements, the doctors will carefully review your unique medical history, including your specific type of adenoid cystic carcinoma, how it has progressed, and any previous treatments you've had. This is to make sure the study treatment is the right fit for your situation and to ensure your safety.
There might be other health conditions or medications that would mean you couldn't join. The study team will discuss all the details with you to see if you meet all the necessary criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have adenoid cystic carcinoma?
- Has your cancer come back or spread?
- Are you able to attend regular clinic visits and appointments?
- Are you willing to complete quality of life questionnaires?
What does participation involve?
If you decide to take part in this study, you will receive the new treatment called Pluvicto. This medicine is given as a liquid, either through an injection or directly into your bloodstream over time, similar to how some other medicines are given. You would have regular visits to the clinic for this treatment and for various health checks.
Throughout the study, doctors will closely monitor your health. This includes regular scans, like CT scans, to see how the cancer is responding to the treatment. They will also ask you to complete questionnaires about your quality of life, which helps them understand how you are feeling day-to-day. You will be monitored for at least two years after finishing your treatment to see the long-term effects. The study team will explain the exact schedule of visits, treatments, and tests.
Potential risks and benefits
Locations (1)
- —UnverifiedPoland
Common questions
What is adenoid cystic carcinoma?
It's a rare type of cancer that usually starts in the salivary glands, which produce spit in your mouth and throat.
What is Pluvicto?
Pluvicto is the new medicine being tested. It's a special type of treatment that targets cancer cells using a certain substance.
What does 'recurrent and/or metastatic' mean?
This means the cancer has either come back after treatment or has spread from where it started to other parts of your body.
Will I definitely get the new treatment?
Yes, in this type of study, all participants who are eligible will receive the Pluvicto treatment.
What is a 'Phase II' study?
Phase II means this is an early stage of testing where doctors are mainly looking at how safe the treatment is and if it shows signs of working well.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.